Mature neutrophils and a NF-κB-to-IFN transition determine the unifying disease recovery dynamics in COVID-19성숙한 호중구와 NF-κB에서 IFN으로의 전환은 COVID-19에서 통합된 질병 회복 역학을 결정합니다Article Published on 2022-06-212022-09-11 Journal: Cell Reports Medicine [Category] 바이오마커, 유전자 메커니즘, [키워드] Blood Cell cell deconvolution cellular cellular and molecular Cellular and molecular mechanisms changes changes in clinically courses COVID-19 decrease determine differentiation disease disease modeling disease recovery Effect framework Gene regulation heterogeneous homeostasis immune immunology implication indication interferon Kinetics mechanisms Medicine neutrophil NF-κB other disease other diseases outcome Patient presenting Regulatory restoration resulting severe COVID-19 Systems biology T cell T cell activation the disease tissues transcriptomes viral infection [DOI] 10.1016/j.xcrm.2022.100652 PMC 바로가기 [Article Type] Article
Coronaviral Infection and Interferon Response: The Virus-Host Arms Race and COVID-19코로나바이러스 감염과 인터페론 반응: 바이러스 숙주 군비 경쟁과 COVID-19Review Published on 2022-06-212022-09-11 Journal: Viruses [Category] COVID19(2023년), SARS, 치료기술, 치료제, [키워드] acute respiratory syndrome acute respiratory syndrome coronavirus acute respiratory syndrome coronavirus 2 Antiviral antiviral drug Arm caused cellular clinical trials coronavirus Coronavirus infection COVID-19 COVID-19 patient Defense Early detection effective functional host cell host cells Hypothesis innate immune interact Interaction interferon Mild morbidity morbidity and mortality no symptoms pandemic Pathogenesis pathway Pattern recognition pattern recognition receptor Pattern recognition receptors pattern-recognition receptor. PRR PRRs race receptor reduce SARS-CoV-2 SARS-COV-2 infection SARS-CoV-2 protein SARS-CoV-2 proteins secretion severe acute respiratory syndrome Coronavirus severe COVID-19 shown signaling pathway suffered susceptibility Variability virus [DOI] 10.3390/v14071349 PMC 바로가기 [Article Type] Review
Specific Antibody and the T-Cell Response Elicited by BNT162b2 Boosting After Two ChAdOx1 nCoV-19 in Common Variable Immunodeficiency공통 가변성 면역 결핍증에서 2개의 ChAdOx1 nCoV-19 후 BNT162b2 부스팅에 의해 유도된 특정 항체 및 T-세포 반응Article Published on 2022-06-172022-09-11 Journal: Frontiers in Immunology [Category] COVID19(2023년), MERS, SARS, 바이오마커, 진단, 치료기술, [키워드] acute respiratory syndrome acute respiratory syndrome coronavirus acute respiratory syndrome coronavirus-2 anti-SARS-CoV-2 anti-SARS-CoV-2 antibodies anti-SARS-CoV-2 immunoglobulin Anti-spike antibody autologous BNT162b2 BNT162b2 vaccine booster vaccination CD19 CD19+ CD3+ CD3+CD4+ CD3+CD8+ CD4+ CD45 CD45+ CD8+ Cell cell count cell counts cell-mediated response ChAdOx1 ChAdOx1 nCoV-19 changes in common common variable immunodeficiency common variable immunodeficiency (CVID) Control Coronavirus-2 COVID-19 infection cumulative cut-off value CVID decrease ELISPOT ELISpot assay evaluated except for flow cytometric healthy control healthy controls healthy individual healthy individuals humoral IFN-γ IFN-γ ELISPOT IFN-γ ELISpot assay IFN-γ producing T cells immune response immunodeficiency Immunoglobulin Immunoglobulin G immunosuppressive immunosuppressive therapy individual interferon interferon-γ Killer cell less Lymphocytes measure morbidity natural killer natural killer cell not different not significant Patient patients positive Primary Immunodeficiency producing protein S raised receiving response Severe acute respiratory syndrome severe acute respiratory syndrome Coronavirus severe acute respiratory syndrome coronavirus-2 shown Side effects significant difference significant differences significantly significantly lower Specific statistically stem cell Stem cell transplantation T cell T cell response T cells tested therapy These data vaccination Vaccinations variable virus-specific T cell virus-specific T-cell with COVID-19 [DOI] 10.3389/fimmu.2022.907125 PMC 바로가기 [Article Type] Article
Salivary, serological, and cellular immune response to the CoronaVac vaccine in health care workers with or without previous COVID-19이전 COVID-19 유무에 관계없이 의료 종사자의 CoronaVac 백신에 대한 타액, 혈청 및 세포 면역 반응Article Published on 2022-06-162022-09-11 Journal: Scientific Reports [Category] COVID19(2023년), MERS, SARS, 변종, 진단, 치료기술, [키워드] analysed anti-SARS-CoV-2 antibodies Cellular immune response chemiluminescence CoronaVac COVID-19 Delta dose ELISA evaluated Evidence flow cytometry Gamma Health care Health care worker health care workers IFN-γ IFN-γ producing T cells IgA IgG anti-spike antibody IgG antibodies IgG antibody immunized inactivated individual individuals induce infected individuals interferon investigated neutralization test Neutralizing activity post-vaccine response producing provide reactive reduced reference strain response Saliva salivary SARS-CoV-2 SARS-CoV-2 variant serological serum serum antibodies serum antibody specific serum Spike protein T cell T cells T-cell the spike protein uninfected vaccinated individual vaccinated individuals Vaccine variable variants virus virus neutralization test [DOI] 10.1038/s41598-022-14283-x PMC 바로가기 [Article Type] Article
Gelatin Stabilizes Nebulized Proteins in Pulmonary Drug Delivery against COVID-19젤라틴은 COVID-19에 대한 폐 약물 전달에서 분무된 단백질을 안정화합니다Article Published on 2022-06-132022-09-11 Journal: ACS Biomaterials Science & Engineering [Category] Coronavirus, COVID19(2023년), SARS, 변종, [키워드] ACE2 acute respiratory syndrome acute respiratory syndrome coronavirus addition Aerogen airway angiotensin angiotensin-converting enzyme 2 biological molecule biological molecules can be used coordination coronavirus CoV-19 COVID-19 delivery distribution domain dosage drug effective ENhance enzyme experiment experiments feasibility fraction Fractions gelatin gelatin stabilization generate IFN-α2 infection with SARS-CoV-2 inhalation inhalation therapy inhibit interferon lung Lungs medication nebulization noninvasive pandemic Protein protocol pulmonary pulmonary delivery RBD-62 respiratory diseases SARS-CoV-2 significantly therapy transfer Vaccines variants [DOI] 10.1021/acsbiomaterials.2c00419 PMC 바로가기 [Article Type] Article
Nucleopore Traffic Is Hindered by SARS-CoV-2 ORF6 Protein to Efficiently Suppress IFN-β and IL-6 SecretionIFN-β 및 IL-6 분비를 효율적으로 억제하기 위해 SARS-CoV-2 ORF6 단백질에 의해 핵공 이동이 방해됨Article Published on 2022-06-112022-09-11 Journal: Viruses [Category] COVID19(2023년), SARS, 유전자 메커니즘, [키워드] Activation addition antagonistic antiviral response block cascade characterized clinical outcomes contributing to counteract Critical cytokine Cytokines cytoplasm cytoplasmic demonstrated ENCODE exacerbated Factors feature Genes Host host immune system IFN-β IL-6 immune immune evasion Infection Inflammation interferon interferon antagonist interleukin interleukin-6 MAVS MDA-5 mechanism Messenger RNA movement mRNA multifunctional NF-κB not affected novel SARS-CoV-2 virus nuclear translocation nucleus occurred ORF6 pro-inflammatory cytokine pro-inflammatory cytokines Protein reported RIG-I SARS-CoV-2 SARS-CoV-2 ORF6 protein SARS-CoV-2 virus Signaling STAT suppresse suppression the SARS-CoV-2 Traffic transcription factor transcription factors transcriptional viral infection viral pathogenesis virulence virus [DOI] 10.3390/v14061273 PMC 바로가기 [Article Type] Article
Intravenous Injection of Coronavirus Disease 2019 (COVID-19) mRNA Vaccine Can Induce Acute Myopericarditis in Mouse Model코로나바이러스 질환 2019(COVID-19) mRNA 백신의 정맥 주사가 마우스 모델에서 급성 심근염을 유발할 수 있음Article Published on 2022-06-102022-09-12 Journal: Clinical Infectious Diseases: An Official Publicat [Category] COVID19(2023년), MERS, SARS, 진단, [키워드] acute respiratory syndrome antigen expression Apoptosis Ballooning degeneration Blood Can cardiac Cardiac pathology change changes clinical manifestations coronavirus coronavirus disease COVID-19 COVID-19 mRNA vaccine different time point dose Evidence evidenced hepatocyte histological change histopathological IL-6 immunization immunostaining in vivo induce infiltrating immune cell inflammatory cell infiltration injection interferon intracardiac intramuscular intravenous Intravenous injection Messenger RNA mice Model mouse mouse model mRNA mRNA expression mRNA vaccine myocytes Myopericarditis Necrosis other organ provided reduce reported risk SARS-CoV-2 serum Serum level significantly significantly higher skeletal tissue Vaccine vaccine injection Vaccines vascular endothelial cells visceral weight loss Withdrawal [DOI] 10.1093/cid/ciab707 PMC 바로가기 [Article Type] Article
High Incidence of SARS-CoV-2 Variant of Concern Breakthrough Infections Despite Residual Humoral and Cellular Immunity Induced by BNT162b2 Vaccination in Healthcare Workers: A Long-Term Follow-Up Study in Belgium의료 종사자의 BNT162b2 백신 접종으로 유도된 잔류 체액 및 세포 면역에도 불구하고 우려되는 돌발 감염의 SARS-CoV-2 변종 높은 발생: 벨기에의 장기 추적 연구Clinical Trial Published on 2022-06-092022-09-11 Journal: Viruses [Category] COVID19(2023년), MERS, SARS, 변종, 임상, 진단, [키워드] activated acute respiratory syndrome acute respiratory syndrome coronavirus acute respiratory syndrome coronavirus 2 Adaptive immune response Alpha analyzed antibody B cell B cells Belgium binding BNT162b2 BNT162b2 vaccine Breakthrough infection breakthrough infections caused CD4 CD8 Cellular immune response cellular immunity circulating concern coronavirus COVID-19 delta variant delta VoCs domain Follow-up functional healthcare healthcare worker Healthcare workers humoral immune responses immunoassays in vitro incidence individual induced initiated interferon interferon-γ investigated Long-term follow-up Long-term monitoring mitigate MONITOR neutralization not correlated performed pseudovirus reduced reported residual respiratory SARS-CoV-2 SARS-CoV-2-specific T cell SARS-CoV-2-specific T cells serology severe acute respiratory syndrome Coronavirus single-center subject symptomatic T cells Trial vaccination Vaccine-induced immunity variant variants variants of concern was determined were assessed [DOI] 10.3390/v14061257 PMC 바로가기 [Article Type] Clinical Trial
Identification of bronchoalveolar and blood immune-inflammatory biomarker signature associated with poor 28-day outcome in critically ill COVID-19 patients중환자 COVID-19 환자에서 좋지 않은 28일 결과와 관련된 기관지 폐포 및 혈액 면역 염증 바이오마커 식별Article Published on 2022-06-092022-09-11 Journal: Scientific Reports [Category] COVID19(2023년), MERS, SARS, 바이오마커, 치료기술, [키워드] acute respiratory syndrome acute respiratory syndrome coronavirus acute respiratory syndrome coronavirus 2 Admission assays BAL BAL fluid BALF Biological biological profile biomarker signature Blood blood concentration bronchoalveolar Bronchoalveolar lavage Characteristics clinical Clinical outcome Concentration coronavirus coronavirus disease Coronavirus disease 2019 COVID-19 COVID-19 patient COVID-19 patients Critical Critically ill critically ill COVID-19 patients Critically ill patient critically ill patients cytokine defined described eicosanoid Eicosanoids elicited ELISA endothelial injury exhibited fiberoptic bronchoscopy Health Organization identification IFN-γ IL-10 IL-22 IL-5 IL-6 Infection Inflammatory response intensive care intensive care unit interferon Local metabolomic analysis neutrophil outcome Patient performed phenotype respiratory SARS-CoV-2 scale severe acute respiratory syndrome Coronavirus type I interferon Vascular Vasoactive VEGF WHO-CPS World Health Organization [DOI] 10.1038/s41598-022-13179-0 PMC 바로가기 [Article Type] Article
Characterization of SARS-CoV-2 Evasion: Interferon Pathway and Therapeutic OptionsSARS-CoV-2 회피의 특성화: 인터페론 경로 및 치료 옵션Review Published on 2022-06-082022-09-11 Journal: Viruses [Category] COVID19(2023년), SARS, 변종, 유전자 메커니즘, 치료제, [키워드] acute respiratory syndrome acute respiratory syndrome coronavirus antagonism Antiviral antiviral therapy characterization characterized circumvent contribute Control Coronavirus-2 COVID-19 COVID-19 pandemic COVID-19 patients Critical critical state drug dysregulated Efficacy evade explain expression Factor helping host innate immunity IFN IFN response IFN signaling pathway IFN-III IFNs in some individual Infection inhibit innate immune innate immune response Innate immunity interferon interferon-stimulated gene ISG mechanism new SARS-CoV-2 option pathogenicity Pathways pro-inflammatory cytokine responsible robust SARS-CoV-2 SARS-COV-2 infection SARS-CoV-2 pathogenesis Severe acute respiratory syndrome severe acute respiratory syndrome Coronavirus severe acute respiratory syndrome coronavirus-2 the disease therapy treat Vaccines variant virus virus–host interactions [DOI] 10.3390/v14061247 PMC 바로가기 [Article Type] Review